HER4

Elevation Oncology Highlights 2021 Achievements and Outlines Expected 2022 Milestones

Retrieved on: 
Monday, January 10, 2022
Clinical trial, Immunoglobulin G, Sarcoma, Safety, HER3, Gallbladder, Doctor of Pharmacy, Growth, Drug development, Disease, Neuregulin 1, HER2, Risk, Investor, Security (finance), Cholangiocarcinoma, Goal, Cancer, Patient, Board, Conference, Trial of the century, U.S. Securities and Exchange Commission, HER4, Lung, Forward-looking statement, NRG1, Oncology, Partnership, Pharmacist, Erosion (morphology), Cell, Private Securities Litigation Reform Act, EGFR, Company, Doctor of Philosophy, Nasdaq, Cohort, Breast, COVID-19, Therapy, Biotechnology, Pharmaceutical industry, Medical imaging, Seribantumab, Neoplasm, MD

NEW YORK, Jan. 10, 2022 /PRNewswire/ --Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today highlighted its 2021 corporate achievements and outlined its expected milestones for 2022.

Key Points: 
  • NEW YORK, Jan. 10, 2022 /PRNewswire/ --Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today highlighted its 2021 corporate achievements and outlined its expected milestones for 2022.
  • Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer, will present these corporate priorities on Wednesday, January 12, 2022, at 9:45 a.m.
  • We believe we are well-positioned to deliver on our mission to advance precision medicines for patients with genomically defined cancers."
  • A live audio webcast of Dr. Leland's presentation will be available on January 12, 2022 at 9:45 a.m.

Elevation Oncology's Seribantumab Included as Part of a Case Series Presentation at the Australasian Gastro-Intestinal Trials Group 2021 Annual Scientific Meeting

Retrieved on: 
Thursday, October 14, 2021
Medical research, Patient, Goal, Cell, Neuregulin 1, Sarcoma, Garvan Institute of Medical Research, Program, COVID-19, HER3, Cancer, Private Securities Litigation Reform Act, Lung, Nasdaq, Gallbladder, NRG1, CA19-9, Most, RECIST, Growth, Medical school, Security (finance), UNSW, Breast, Therapy, St Vincent's Hospital, Sydney, Disease, University of Sydney, Oncology, Clinical trial, HER4, HER2, Erosion (morphology), U.S. Securities and Exchange Commission, Biotechnology, Cholangiocarcinoma, Forward-looking statement, Company, University, Trial of the century, EGFR, Safety, Compassion, Risk, Immunoglobulin G, AIDS Clinical Trials Group, Pharmaceutical industry, Medical imaging

"We are pleased to have been able to gain access to an investigational treatment option for this patient, following identification of an NRG1 fusion.

Key Points: 
  • "We are pleased to have been able to gain access to an investigational treatment option for this patient, following identification of an NRG1 fusion.
  • Elevation Oncology expects to report clinical data from an interim analysis of the CRESTONE study in mid-2022.
  • Seribantumab is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3).
  • The NRG1 fusion protein is often also able to activate the HER3 pathway, leading to unregulated cell growth and proliferation.

Spectrum Pharmaceuticals Announces Presentation of Poziotinib in Combination with KRASG12C Inhibitors at the 2021 AACR-NCI-EORTC Conference

Retrieved on: 
Thursday, October 7, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Treatment, NCI, EGFR, Medication, Therapy, MD Anderson Cancer Center, American Association for Cancer Research, Conference, 8-K, HER3, University of Texas at Austin, NSCLC, Forward-looking statement, HER4, Spectrum Pharmaceuticals, Humanitarian use licenses, Annual report, SEC, KRAS, Research, FDA, U.S. Securities and Exchange Commission, Nasdaq, EORTC, University, HER, Security (finance), AACR, Monroe Dunaway Anderson, National, Quality control, American Association, Association, Assistant professor, Patient, SPPI, European Organization for Quality, National Cancer Institute, Poziotinib, HER2, Pharmaceutical industry

The preclinical data demonstrated that inhibition of EGFR, HER2, HER3, and HER4 signaling by the pan-ErbB inhibitor poziotinib was synergistic when combined with KRASG12C inhibitors.

Key Points: 
  • The preclinical data demonstrated that inhibition of EGFR, HER2, HER3, and HER4 signaling by the pan-ErbB inhibitor poziotinib was synergistic when combined with KRASG12C inhibitors.
  • These results highlight the importance of HER3 and HER4 signaling, in addition to EGFR and HER2, after KRASG12C inhibition.
  • SPECTRUM PHARMACEUTICALS, INC. is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial

Retrieved on: 
Friday, October 1, 2021
Mortality, CNS, Glioblastoma, Clinical trial, Cancer, ErbB, GBM, Hope, Epidermal growth factor receptor, HER2/neu, HER2, Patient, ERBB4, Brain, III, T790M, Population, Central nervous system, Disease, Immune system, Lung cancer, Phase, NSCLC, CA, Principal, HER4, Company, Large-cell lung carcinoma, Entrepreneurship, MBA, TKI, Survival, Safety, Incidence, EGFR, Quality of life, Doctor of Philosophy, Breast cancer, Pharmaceutical industry, Medical imaging

"Our preclinical studies have shown that EO1001 is potent against multiple activating mutations in the intracellular domain of EGFR.

Key Points: 
  • "Our preclinical studies have shown that EO1001 is potent against multiple activating mutations in the intracellular domain of EGFR.
  • The Phase I/IIa clinical trial will enroll up to 50 patients and is being conducted in Australia under contract service provided by Senz Oncology Pty Ltd.
  • The objective of this first-in-human clinical trial is to examine the safety and tolerability of EO1001 in patients with metastatic or advanced stage ErbB-1(EGFR), ErbB-2(HER2) and/or ERbB-4 (HER4) positive cancer.
  • On February 9, 2021, Edison Oncology and Apollomics announced an exclusive licensing agreement whereby Apollomics will develop and commercialize EO1001 (APL-122) globally, except in Mainland China, Hong Kong and Taiwan.

Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial

Retrieved on: 
Thursday, September 30, 2021
Mortality, CNS, Glioblastoma, Clinical trial, Cancer, ErbB, Hope, Epidermal growth factor receptor, HER2/neu, HER2, Patient, ERBB4, Brain, III, T790M, Population, Central nervous system, Disease, Lung cancer, Phase, NSCLC, Principal, HER4, GBM, Large-cell lung carcinoma, Entrepreneurship, MBA, TKI, Survival, Safety, Incidence, EGFR, Quality of life, Doctor of Philosophy, Breast cancer, GLOBE, Pharmaceutical industry, Medical imaging

Our preclinical studies have shown that EO1001 is potent against multiple activating mutations in the intracellular domain of EGFR.

Key Points: 
  • Our preclinical studies have shown that EO1001 is potent against multiple activating mutations in the intracellular domain of EGFR.
  • The Phase I/IIa clinical trial will enroll up to 50 patients and is being conducted in Australia under contract service provided by Senz Oncology Pty Ltd.
  • The objective of this first-in-human clinical trial is to examine the safety and tolerability of EO1001 in patients with metastatic or advanced stage ErbB-1(EGFR), ErbB-2(HER2) and/or ERbB-4 (HER4) positive cancer.
  • On February 9, 2021, Edison Oncology and Apollomics announced an exclusive licensing agreement whereby Apollomics will develop and commercialize EO1001 (APL-122) globally, except in Mainland China, Hong Kong and Taiwan.